Akari Therapeutics, Plc Foreign Pre-Tax Income
Akari Therapeutics, Plc (AKTX) reported Foreign Pre-Tax Income of $1.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign · last filed 2026-03-30
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, foreign for fiscal 2025 was $1.38M.
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, foreign for fiscal 2024 was -$367.00K, a 241.70% decline from fiscal 2023.
- Akari Therapeutics, Plc income (loss) from continuing operations before income taxes, foreign for fiscal 2023 was $259.00K.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.38M 10-K · filed 2026-03-30 | |
| 2024-12-31 | -$367.00K 10-K · filed 2026-03-30 | |
| 2023-12-31 | $259.00K 10-K · filed 2025-04-15 | $259.00 10-K · filed 2024-03-29 |
| 2022-12-31 | -$2.94M 8-K · filed 2024-09-06 | $269.85K 20-F · filed 2023-05-01 |
| 2021-12-31 | -$115.45K 20-F · filed 2023-05-01 | |
| 2020-12-31 | $312.46K 20-F · filed 2023-05-01 | $312.46K 20-F · filed 2021-04-21 |
| 2019-12-31 | $24.50K 20-F · filed 2022-05-16 | |
| 2018-12-31 | $133.60K 20-F · filed 2021-04-21 | |
| 2017-12-31 | -$103.64K 20-F · filed 2020-03-31 | |
| 2016-12-31 | -$184.83K 20-F · filed 2019-04-23 | |
| 2015-12-31 | -$5.72M 20-F · filed 2018-07-18 | |
| 2014-12-31 | -$1.61M 20-F · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |